Table 2.
QCA analysis results with parsimonious solution.
| Personalization | Formula No | Explanatory formula | Drug |
|---|---|---|---|
| Yes | (1) | Indication is squamous NSCLC only {No} and Orphan drug designation {Yes} | Afatinib, alectinib, ceritinib, crizotinib, dabrafenib, dacomitinib, gefitinib, osimertinib, trametinib |
| (2) | The personalized strategy is used prior to NSCLC indication in the US {No} and Immuno-oncology target {Yes} and First line {Yes} | atezolizumab, cemiplimab, ipilimumab, nivolumab | |
| (3) | Indication is squamous NSCLC only {No} and Immuno-oncology target {No} and First in class for the target {No} | Afatinib, alectinib, ceritinib, dacomitinib, erlotinib, gefitinib, osimertinib, ramucirumab | |
| (4) | Orphan drug designation {No} and Immuno-oncology target {No} and First in class for the target {No} | erlotinib, ramucirumab | |
| (5) | Orphan drug designation {Yes} and First in class for the target {Yes} | Crizotinib, dabrafenib, trametinib | |
| No | (6) | Indication is squamous NSCLC only {Yes} | Afatinib, necitumumab, nivolumab |
| (7) | The personalized strategy is used prior to NSCLC indication in the US {Yes} and Immuno-oncology target {Yes} | Pembrolizumab | |
| (8) | Orphan drug designation {No} and First line {No} | Atezolizumab, erlotinib, nivolumab, pemetrexed disodium, ramucirumab | |
| (9) | Orphan drug designation {No} and Immuno-oncology target {No} and First in class for the target {Yes} | bevacizumab, erlotinib, paclitaxel protein-bound particle, pemetrexed disodium, ramucirumab | |
| (10) | Immuno-oncology target {Yes} and First line {No} | Atezolizumab, durvalumab, nivolumab | |
| (11) | First in class for the target {Yes} and First line {No} | Atezolizumab, erlotinib, nivolumab, pemetrexed disodium, ramucirumab |